EP0177920A2 - Arzneimittel zur externen Anwendung enthaltend aktives Vitamin-D3 - Google Patents

Arzneimittel zur externen Anwendung enthaltend aktives Vitamin-D3 Download PDF

Info

Publication number
EP0177920A2
EP0177920A2 EP85112679A EP85112679A EP0177920A2 EP 0177920 A2 EP0177920 A2 EP 0177920A2 EP 85112679 A EP85112679 A EP 85112679A EP 85112679 A EP85112679 A EP 85112679A EP 0177920 A2 EP0177920 A2 EP 0177920A2
Authority
EP
European Patent Office
Prior art keywords
composition
carrier
dihydroxycholecalciferol
active
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP85112679A
Other languages
English (en)
French (fr)
Other versions
EP0177920A3 (en
EP0177920B1 (de
Inventor
Yuji Makino
Yoshiki Suzuki
Takashi Aoyagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP20963184A external-priority patent/JPS6187619A/ja
Priority claimed from JP16289385A external-priority patent/JPS6226223A/ja
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to AT85112679T priority Critical patent/ATE56362T1/de
Publication of EP0177920A2 publication Critical patent/EP0177920A2/de
Publication of EP0177920A3 publication Critical patent/EP0177920A3/en
Application granted granted Critical
Publication of EP0177920B1 publication Critical patent/EP0177920B1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems

Definitions

  • This invention relates to a pharmaceutical composition for external use containing active-type vitamin D 3 .
  • Active-type vitamins D 3 such as la,25-dihydroxycholecalciferol, la, 2 4-dihy d roxycholecalciferol and la-hydroxycholecalciferol are hormones which promote absorption and transportation of calcium in the small intestine, regulate bone absorption and bone resorption in bones and suppress secretion of parathyroid hormone in the parathyroid (U. S. Patents Nos. 3,901,928 and 4,022,891 and Tetrahedron Letters, 40, 4147, 1972).
  • the active-type vitamins D 3 are used for the treatment of renal failure and osteomalacia in which active-type vitamins D J are insufficient and absorption of calcium is reduced, osteoporosis which is a disease associated with abnormal bone metabolism, and rickets showing the insufficiency of vitamin D J (Basic Research and Its Clinical Applications, 1099-1106, 1979).
  • Japanese Laid-Open Patent Publication No. 26820/ 1981 suggests the usability of active-type vitamin D J as an agent for suppressing immune function, for example as an agent for treating articular rheumatism.
  • Japanese Laid-Open Patent Publication No. 149224/ 1982 sugggests the usability of active-type vitamin D 3 as an agent for inducing differentiation of cancer cells. It suggests that active-type vitamins D 3 promote differentiation of cancer cells at certain local sites of the cells and thus inhibit proliferation of the cancer cells.
  • European Laid-Open Patent Application No. 0123948 and the corresponding U. S. Patent Application Serial No. 595,835 disclose a pharmaceutical composition for external use containing a glycerol ester of pyroglutamic acid as a drug penetration enhancer.
  • This pharmaceutical composition can be applied to the skin or mucosa of a warm-blooded animal.
  • the specifications of the above patent documents disclose the glycerol ester can be used as a penetration enhancer for various drugs such as anti-inflammatory agents, agents for the cirulatory system, antimicrobial agent, anti-ulcer agents, analgesic agents, anticancer agents, antiemetic agents, anti-allergic agents, agents for the central nervous system, agents for the peripheral nervous system, biologicals and agents for the metabolic system.
  • the above specifications give several examples of active-type vitamin D 3 as the agents for the metabolic system.
  • Example 132 of these documents discloses an ointment comprising 1 «-hydroxycholecalciferol as a drug and the above glycerol ester as the penetration enhancer.
  • these specifications fail to describe anything on the usability of this composition for the treatment of articular rheumatism, cancer or psoriasis.
  • European Patent Application No. 85111034.6 discloses alkyl or alkenyl esters of pyroglutamic acid as penetration enhancers effective for many drugs similar to those described in the specification of European Laid-Open Patent Application No. 0123948.
  • European Patent Application No. 85111034.6 does not give an example of a specific composition comprising active-type vitamin D 3 nor describe anything on the usability of such a composition for the treatment of articular rheumatism, etc.
  • Another object of this invention is to provide a stable pharmaceutical composition for external use comprising active-type vitamin D 3 in which the active-type vitamin D 3 can be protected from decomposition by water or moisture during formulation or storage.
  • Still another object of this invention is to provide a pharmaceutical composition for external use comprising active-type vitamin D J in which the concentration of the active-type vitamin D J at a local site is increased and maintained high for an extended period of time.
  • Yet another object of this invention is to provide a pharmaceutical composition for external use comprising active-type vitamin D 3 in which the concentration of the active-type vitamin D 3 at a local site is rendered high, whereas the amount of the vitamin D J to be circulated through the body is reduced to increase its bioavailability and avoid its side-effects such as hypercalcemia.
  • a further object of this invention is to provide a pharmaceutical composition for external use comprising active-type vitamin D 3 which can improve articular rheumatism efficiently when applied to the skin near the site of that disease.
  • a still further object of this invention is to provide a pharmaceutical composition for external use comprising active-type vitamin D 3 which is effective with very good efficiency for the improvement and disappearance of a proriatic site of the skin by direct application thereto.
  • compositions for external application to the skin of a warm-blooded animal comprising
  • Examples of the active-type vitamin D 3 used in this invention include
  • la-hydroxycholecalciferol (to be sometimes written as 1 ⁇ -OH-D 3 for short), la,25-dihydroxycholecalciferol [1 ⁇ ,25-(OH) 2 -D 3 for short], 1 ⁇ ,24-dihydroxycholecalciferol [1 ⁇ ,24-(OH) 2 -D 3 for short], la,24,25-tri- hydroxycholecalciferol [1 ⁇ ,24,25-(OH) 3 -D 3 for short], 25-hydroxycholecalciferol (25-OH-D 3 for short), 24-hydroxycholecalciferol (24-OH-D 3 for short), 24,25-dihydroxycholecalciferol [24,25-(OH) 2 -D 3 for short], 26-chloro- la,24(R)-dihydroxycholecalciferol, 24,24-difluoro-la,25-dihydroxycholecalciferol and 26,26,26,27
  • the carrier itself may be hydrophilic or oleophilic.
  • a hydrophilic carrier it is necessary to ensure that the composition does not contain water, and during formulation or storage, the composition is isolated from water or moisture.
  • Preferred carriers used in the composition of this invention are substantially water-immiscible.
  • examples are hydrocarbons, silicones, higher alcohols, sterols, sterol esters, higher fatty acids, higher fatty acid esters, fatty acid triglycerides, pressure-sensitive adhesive acrylic polymers, and mixtures of these.
  • the hydrocarbons are preferably selected from the group consisting of white vaseline, yellow vaseline, paraffins (hard paraffins and paraffin waxes), microcrystalline waxes, polyethylene, squalane, squalene, etc.
  • the higher alcohols are preferably selected from the group consisting of myristyl alcohol, lauryl alcohol, cetyl alcohol, stearyl alcohol, cetostearyl alcohol, oleyl alcohol, anethole, citronellol, eugenol, etc.
  • Polyhydric alcohols such as propylene glycol and glycerin can also be used as the carrier.
  • the pressure-sensitive adhesive acrylic polymers are preferably those comprising C 4 -C 12 alkyl esters of acrylic or methacrylic acid, such as butyl acrylate, 2-ethylhexyl acrylate or octyl acrylate, as a major component.
  • composition of this invention may further include a chemical component different from the carrier, for example a structural matrix agent such as colloidal silica, bentonite or montmorillonite; an antioxidant such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, pyrogallol, hydroxyquinone, hydroxy- coumarin and tocopherols; an antiseptic such as phenol, cresol, parabens, benzyl alcohol, sorbic acid and quaternary ammonium compound; an absorption promoter selected from the group consisting of propylene glycol, oleic acid, urea, higher fatty acid esters of sucrose, diisopropyl adipate, diethyl sebacate, isopropyl myristate, hexyl laurate, dimethyl sulfoxide and mixtures of these; and a coloring agent such as 9-ortho-carboxyphenyl-6-hydroxy-2
  • the pharmaceutical composition for external use provided by this invention are suitable for the treatment of articular rheumatism, cancer (e.g., skin cancer or uterus cancer), and various types of psoriasis such as psoriasis vulgaris, pustular psoriasis, guttate psoriasis and erythroderma-type psoriasis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP85112679A 1984-10-08 1985-10-07 Arzneimittel zur externen Anwendung enthaltend aktives Vitamin-D3 Expired EP0177920B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT85112679T ATE56362T1 (de) 1984-10-08 1985-10-07 Arzneimittel zur externen anwendung enthaltend aktives vitamin-d3.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP20963184A JPS6187619A (ja) 1984-10-08 1984-10-08 活性型ビタミンｄ↓３類外用剤
JP209631/84 1984-10-08
JP16289385A JPS6226223A (ja) 1985-07-25 1985-07-25 乾癬治療剤
JP162893/85 1985-07-25

Publications (3)

Publication Number Publication Date
EP0177920A2 true EP0177920A2 (de) 1986-04-16
EP0177920A3 EP0177920A3 (en) 1987-06-03
EP0177920B1 EP0177920B1 (de) 1990-09-12

Family

ID=26488518

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85112679A Expired EP0177920B1 (de) 1984-10-08 1985-10-07 Arzneimittel zur externen Anwendung enthaltend aktives Vitamin-D3

Country Status (6)

Country Link
US (1) US4871723A (de)
EP (1) EP0177920B1 (de)
CA (1) CA1272953A (de)
DE (1) DE3579655D1 (de)
FR (1) FR99C0035I2 (de)
MY (1) MY101544A (de)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0198213A3 (en) * 1985-03-15 1987-05-20 Yeda Research And Development Company, Ltd. Method and compositions comprising a vitamin d derivative for the local treatment of bone fractures
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
DE4020511A1 (de) * 1989-07-28 1991-01-31 Kureha Chemical Ind Co Ltd Stabile pharmazeutische zusammensetzung enthaltend 24,25-dihydroxycholecalcipherol als einen wirkstoff
EP0437225A1 (de) * 1990-01-10 1991-07-17 F. Hoffmann-La Roche Ag Topische Präparate
US5037816A (en) * 1984-11-02 1991-08-06 The General Hospital Corporation Method of treating psoriasis
WO1991012792A1 (en) * 1990-03-02 1991-09-05 The Partnership Of Isaac G. Eliaz And Shmuel Gonen Method and product for promoting hair growth and treating skin conditions
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
US5254538A (en) * 1989-10-04 1993-10-19 Trustees Of Boston University Method of treating periodontal disease
EP0588539A1 (de) * 1992-09-18 1994-03-23 Teva Pharmaceutical Industries, Ltd. Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
EP0581587A3 (de) * 1992-07-31 1995-05-17 Tanabe Seiyaku Co Grundstoff zur transdermalen Verabreichung.
US5902806A (en) * 1996-02-28 1999-05-11 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
US6203782B1 (en) 1990-03-02 2001-03-20 Universal Biologics, Inc. Method and product for promoting hair growth and treating skin conditions
EP0979654A4 (de) * 1998-03-04 2002-05-08 Teijin Ltd Emulsionsformige aktivierte vitamin-d3 enthaltende lotione
US6538039B2 (en) * 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
US9173835B2 (en) 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175235B1 (da) * 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
US5061700A (en) * 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5486509A (en) * 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
CA2148109C (en) * 1993-09-01 1999-11-23 Yuji Makino 1.alpha., 24-(oh)2-v.d.3 emulsion composition
FR2710841B1 (fr) * 1993-10-05 1995-11-17 Oreal Composition cosmétique ou pharmaceutique pour la peau, anhydre et stable, à base de rétinol et son utilisation en vue du traitement des maladies de la peau.
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP1051974A4 (de) * 1997-12-09 2001-09-12 Chugai Pharmaceutical Co Ltd Vitamin-d3-derivate enthaltende lotionen
EP1040832A4 (de) * 1997-12-09 2001-09-12 Chugai Pharmaceutical Co Ltd Vitamin d3 enthaltende cremen
US6491936B1 (en) 1997-12-09 2002-12-10 Chugai Seiyaku Kabushiki Kaisha Creams containing vitamin D3 derivatives
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
AUPP583198A0 (en) * 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
FR2871694B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
FR2884419B1 (fr) * 2005-04-19 2007-06-22 Galderma Sa Composition de type solution filmogene comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
EP1874320A1 (de) * 2005-04-19 2008-01-09 Galderma S.A. Zusammensetzung für eine filmbildende lösung mit vitamin d oder einem derivat davon und einem corticosteroiden und ihre verwendung in der dermatologie
FR2885527B1 (fr) * 2005-05-16 2007-06-29 Galderma Res & Dev Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou ses derives a l'etat solubilise
EP2526930B1 (de) * 2005-06-01 2013-12-25 GlaxoSmithKline Intellectual Property Development Limited Vitaminformulierung
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP1970049A1 (de) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topische Zusammensetzung mit Vitamin D und Kortikosteroid
EP2008651A1 (de) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited Biologisch erodierbares Patch
HRP20191711T1 (hr) 2011-03-14 2019-12-13 Drug Delivery Solutions Ltd Oftalmološki pripravak
JP5652723B2 (ja) * 2012-08-17 2015-01-14 フォーモサ・ラボラトリーズ・インコーポレーテッド マキサカルシトールの新しい結晶形態
EP3542788A1 (de) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topische zusammensetzung enthaltend calcipotriol und betamethason dipropionat

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2249414A1 (de) 1972-10-09 1974-04-25 Georg Dr Rueckheim Brand- und wundsalbe
US3901928A (en) 1973-01-10 1975-08-26 Robert Henry Hesse 1' ,3' -dihydroxy steroid-5-enes method of preparing same and their use for preparing 1' -hydroxy-25-hydrogen vitamin d compounds
US4022891A (en) 1974-06-18 1977-05-10 Teijin Limited Novel 1α,24-dihydroxycholecalciferol compositions, novel precursors thereof, and processes for preparing them
JPS5626820A (en) 1979-08-10 1981-03-16 Chugai Pharmaceut Co Ltd Immunosuppressing agent
JPS57149224A (en) 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
EP0094644A1 (de) 1982-05-17 1983-11-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verwendung eines Cholecalciferolderivates
GB2124080A (en) 1982-07-26 1984-02-15 Wisconsin Alumni Res Found Vitamin d3 derivatives for preventing milk fever in dairy cattle
EP0123948A1 (de) 1983-04-04 1984-11-07 Teijin Limited Pharmazeutische Zusammensetzung zur äusseren Anwendung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249109A (en) * 1963-11-01 1966-05-03 Maeth Harry Topical dressing
GB1404583A (en) * 1971-10-08 1975-09-03 Vymatt Sa Urea compositions and methods of preparation thereof
FR2389377A1 (en) * 1977-05-06 1978-12-01 Brohult Johan Antiinflammatory, antirheumatic medicament - comprises 1 alpha-hydroxy-cholecalciferol
JPS5452717A (en) * 1977-09-29 1979-04-25 Chugai Pharmaceut Co Ltd Stable oily pharmaceuticals containing 1alpha-hydroxyvitamin d
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS55136229A (en) * 1979-04-10 1980-10-23 Teijin Ltd Adjustment of bone metabolism in warm-blooded animal and drug for it
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
US4338312A (en) * 1981-05-11 1982-07-06 Wisconsin Alumni Research Foundation Method for preventing parturient paresis in dairy cattle
US4442093A (en) * 1981-05-15 1984-04-10 Kureha Kagaku Kogyo Kabushiki Kaisha Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia
GB2126234B (en) * 1982-07-26 1986-05-21 Wisconsin Alumni Res Found Novel vitamin d analogs
US4610978A (en) * 1983-03-22 1986-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
JPS6011422A (ja) * 1983-06-30 1985-01-21 Kureha Chem Ind Co Ltd 抗筋ジストロフイ−症剤
JPS6160620A (ja) * 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
JPS6217A (ja) * 1985-02-14 1987-01-06 Chugai Pharmaceut Co Ltd 安定な活性型ビタミンｄ３類製剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2249414A1 (de) 1972-10-09 1974-04-25 Georg Dr Rueckheim Brand- und wundsalbe
US3901928A (en) 1973-01-10 1975-08-26 Robert Henry Hesse 1' ,3' -dihydroxy steroid-5-enes method of preparing same and their use for preparing 1' -hydroxy-25-hydrogen vitamin d compounds
US4022891A (en) 1974-06-18 1977-05-10 Teijin Limited Novel 1α,24-dihydroxycholecalciferol compositions, novel precursors thereof, and processes for preparing them
JPS5626820A (en) 1979-08-10 1981-03-16 Chugai Pharmaceut Co Ltd Immunosuppressing agent
JPS57149224A (en) 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
EP0094644A1 (de) 1982-05-17 1983-11-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verwendung eines Cholecalciferolderivates
GB2124080A (en) 1982-07-26 1984-02-15 Wisconsin Alumni Res Found Vitamin d3 derivatives for preventing milk fever in dairy cattle
EP0123948A1 (de) 1983-04-04 1984-11-07 Teijin Limited Pharmazeutische Zusammensetzung zur äusseren Anwendung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Abstracts of Papers in the Third Meeting of the Japanese Society of Bone and Mineral Metabolism", 25 June 1985, JAPANESE SOCIETY OF BONE AND MINERAL METABOLISM, pages: 74
CHEM. PHARM. BULL., vol. 21, 1978, pages 2568

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
EP0202276A4 (de) * 1984-11-02 1988-09-28 Gen Hospital Corp Zubereitung zur behandlung von psoriasis.
US5037816A (en) * 1984-11-02 1991-08-06 The General Hospital Corporation Method of treating psoriasis
EP0198213A3 (en) * 1985-03-15 1987-05-20 Yeda Research And Development Company, Ltd. Method and compositions comprising a vitamin d derivative for the local treatment of bone fractures
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
DE4020511A1 (de) * 1989-07-28 1991-01-31 Kureha Chemical Ind Co Ltd Stabile pharmazeutische zusammensetzung enthaltend 24,25-dihydroxycholecalcipherol als einen wirkstoff
US5254538A (en) * 1989-10-04 1993-10-19 Trustees Of Boston University Method of treating periodontal disease
EP0437225A1 (de) * 1990-01-10 1991-07-17 F. Hoffmann-La Roche Ag Topische Präparate
WO1991012792A1 (en) * 1990-03-02 1991-09-05 The Partnership Of Isaac G. Eliaz And Shmuel Gonen Method and product for promoting hair growth and treating skin conditions
US6203782B1 (en) 1990-03-02 2001-03-20 Universal Biologics, Inc. Method and product for promoting hair growth and treating skin conditions
EP0581587A3 (de) * 1992-07-31 1995-05-17 Tanabe Seiyaku Co Grundstoff zur transdermalen Verabreichung.
US5565442A (en) * 1992-09-18 1996-10-15 Teva Pharmaceutical Industries Ltd. Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3
US5804573A (en) * 1992-09-18 1998-09-08 Teva Pharmaceutical Industries Ltd. Stabilized pharmaceutical composition containing derivative of vitamins D2 and D3
EP0588539A1 (de) * 1992-09-18 1994-03-23 Teva Pharmaceutical Industries, Ltd. Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
US6538039B2 (en) * 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
US5902806A (en) * 1996-02-28 1999-05-11 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
EP0979654A4 (de) * 1998-03-04 2002-05-08 Teijin Ltd Emulsionsformige aktivierte vitamin-d3 enthaltende lotione
CZ298971B6 (cs) * 1998-03-04 2008-03-26 Teijin Limited Lotion na bázi emulze aktivního vitamínu D3
US9173835B2 (en) 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
US9603861B2 (en) 2005-05-10 2017-03-28 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases

Also Published As

Publication number Publication date
MY101544A (en) 1991-12-17
DE3579655D1 (de) 1990-10-18
EP0177920A3 (en) 1987-06-03
US4871723A (en) 1989-10-03
CA1272953A (en) 1990-08-21
FR99C0035I1 (de) 1999-11-05
EP0177920B1 (de) 1990-09-12
FR99C0035I2 (de) 2000-08-11

Similar Documents

Publication Publication Date Title
EP0177920B1 (de) Arzneimittel zur externen Anwendung enthaltend aktives Vitamin-D3
US5869090A (en) Transdermal delivery of dehydroepiandrosterone
US5026556A (en) Compositions for the transdermal delivery of pharmaceutical actives
CN1152689C (zh) 活性维生素d3乳状液类型的洗剂
US4610978A (en) Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
EP1511516B1 (de) Topisch anwendbare pharmazeutische zubereitung
DE69331409T2 (de) Oral 1alpha-hydroxyprevitamin d
EP0698393A1 (de) Lösungsvermittler und externe zubereitung, die diesen enthält
AU2010335654B2 (en) Cutaneous composition comprising vitamin D analogue and a mixture of solvent and surfactants
US20080039405A1 (en) Modification of percutaneous absorption of topically active materials
US4983626A (en) Anti-rheumatic agents and their use
EP0357030B1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten
CN102048678A (zh) 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用
US5019395A (en) Compositions with enhanced penetration
US5709878A (en) Transdermal delivery of dehydroepiandrosterone
US5612327A (en) 1α,24-(OH)2 -cholecalciferol emulsion composition and method for treating psoriasis
CN1186435A (zh) 维生素d4衍生物在治疗癌症中的应用
JP2750281B2 (ja) 高コレステロール血症治療剤
NZ236921A (en) Laminate for transmembranal administration of a drug
CA2198517A1 (en) Crystalline vitamin d derivative
KR20080063790A (ko) 활성 비타민 ｄ 화합물을 이용하는 화학 요법 또는 방사선요법과 관련된 위장 및 방광 장애의 예방 및 치료
CA2203566C (en) Percutaneously administration preparation
JP3506505B2 (ja) 白斑治療剤
US20050232983A1 (en) Transdermal patch
WO2021099901A1 (en) Stable topical pharmaceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19870703

17Q First examination report despatched

Effective date: 19881109

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 56362

Country of ref document: AT

Date of ref document: 19900915

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3579655

Country of ref document: DE

Date of ref document: 19901018

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 85112679.7

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: CHSPCFIKS 53310/950829, 951120

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: CHSPCFIKS 53310/950829, 951120

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFF

Free format text: GBCTFFSPC/GB96/020, 960530

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: IKS 53310/950829, 951120, EXPIRES:20100829

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFG

Free format text: GBCTFGSPC/GB96/020, 961011, EXPIRES:20100828

CCPV Be: grant of a complementary protection certificate

Free format text: 097C0030, EXPIRES: 20100829

MED It: supplementary protection certificate for pharmaceutical products: no action taken

Free format text: CCP 643, 19990118; TEIJIN LIMITED

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: TACALCITOL, MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 23 378 19990510; FIRST REGISTRATION: CH - 5331001(KIS) 19950829

Spc suppl protection certif: 99C0035

Filing date: 19990930

Extension date: 20100829

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: TACALCITOL, MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 23 378 19990510; FIRST REGISTRATION: CH - 5331001(KIS) 19950829

Spc suppl protection certif: 99C0035

Filing date: 19990930

REG Reference to a national code

Ref country code: FR

Ref legal event code: CR

Free format text: FRCR 99C0035, 19990930

MEDD It: supplementary protection certificate for pharmaceutical products: granted

Free format text: CCP 643, 19990118; TEIJIN LIMITED

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: 0090010, 991217

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

REG Reference to a national code

Ref country code: FR

Ref legal event code: CY

Free format text: FRCY 99C0035, 990930, EXPIRES: 20100829

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCG

Free format text: 0090010, 20051008, EXPIRES: 20100828

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040921

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20040923

Year of fee payment: 20

Ref country code: GB

Payment date: 20040923

Year of fee payment: 20

Ref country code: CH

Payment date: 20040923

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040924

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20041007

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20041011

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20041206

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20051006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20051007

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

BE20 Be: patent expired

Owner name: *TEIJIN LTD

Effective date: 20051007

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFE

Free format text: SPC/GB96/020: 20051007, EXPIRES: 20100828

Spc suppl protection certif: SPC/GB96/020

Filing date: 20051007

Expiry date: 20100828

EUG Se: european patent has lapsed
NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20051007

BE20 Be: patent expired

Owner name: *TEIJIN LTD

Effective date: 20051007

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCL

Spc suppl protection certif: C00177920/01

Ref country code: BE

Ref legal event code: CCRE

Free format text: PRODUCT NAME: TACALCITOL MONOHYDR; NAT. REGISTRATION NO/DATE: 711 IS 122 F 7 19961216; FIRST REGISTRATION: CH 53310 01 19950829

Spc suppl protection certif: 97C0030

Filing date: 19970521

Expiry date: 20051007

Extension date: 20100829

Effective date: 20100829

REG Reference to a national code

Ref country code: GB

Ref legal event code: SPCE

Free format text: PRODUCT NAME: TACALCITOL; REGISTERED: CH 53310 19950829; UK 11648/0019 19960119

Spc suppl protection certif: SPC/GB96/020

Filing date: 19960530

Expiry date: 20051007

Extension date: 20100828